NSE ScannerMedical Devices & Supplies · Medical Distributors · NSE: BALAXI · data 2026-11-01
Balaxi Pharmaceuticals Limited
In plain words
Price: 56.3% below its 52-week high of ₹43.85.
Delivery: 79.7% of traded shares were kept for delivery over the last 10 sessions, against 78.3% over the last 60.
Latest results: a net profit of ₹1 cr for the quarter ended Jun 2026 (+348.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | — |
| Net profit (last 12 months) | — |
| Sales growth, 3 years (yearly) | -7.0% |
| Profit growth, 3 years (yearly) | -68.6% |
At a glance
Promoters 66.0% (unchanged in a year), pledged 0.0%, institutions 2.6%.
ROE 0.6%, ROCE —: how much profit it earns on the money it uses.
Debt/equity 0.23, Profit growth -68.6% and sales growth -7.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (0.6%).
- Profit fell 68.6% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
BALAXI Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹80.68 crore, up 14.1% YoY and up 14.1% QoQ.
Net profit was ₹1.3 crore, up 348.3% YoY and up 113.1% QoQ.
Operating margin was 5.8% (5.9% a year ago).
EPS was ₹0.24, up 380% YoY and up 118.2% QoQ.
BALAXI के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹80.68 करोड़; पिछले साल की तुलना में 14.1% की बढ़त, पिछली तिमाही की तुलना में 14.1% की बढ़त।
शुद्ध मुनाफ़ा: ₹1.3 करोड़; पिछले साल की तुलना में 348.3% की बढ़त, पिछली तिमाही की तुलना में 113.1% की बढ़त।
ऑपरेटिंग मार्जिन: 5.8% (एक साल पहले 5.9%)।
EPS: ₹0.24; पिछले साल की तुलना में 380% की बढ़त, पिछली तिमाही की तुलना में 118.2% की बढ़त।
BALAXIના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹80.68 કરોડ; ગયા વર્ષની સરખામણીએ 14.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 14.1% વધારો.
ચોખ્ખો નફો: ₹1.3 કરોડ; ગયા વર્ષની સરખામણીએ 348.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 113.1% વધારો.
ઓપરેટિંગ માર્જિન: 5.8% (એક વર્ષ પહેલાં 5.9%).
EPS: ₹0.24; ગયા વર્ષની સરખામણીએ 380% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 118.2% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 75.2% over the last 20 sessions vs 74.9% in the 40 before (1x); shares delivered per day 0.51x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 5 Aug 26Results Q1 FY27 results: profit +348.3% YoY +0.7% next session
- 30 Jun 26Results Q4 FY26 results: profit −92.9% YoY +0.6% next session
- 28 Jan 26Results Q3 FY26 results: profit −94.4% YoY +0.5% next session
- 11 Nov 25Results Q2 FY26 results: profit −95.4% YoY -9.1% next session
- 12 Aug 25Results Q1 FY26 results: profit −95.5% YoY -0.7% next session
- 30 May 25Results Q4 FY25 results: profit −21.0% YoY +6.1% next session
- 10 Feb 25Results Q3 FY25 results: profit −60.6% YoY -6.4% next session
- 5 Nov 24Results Q2 FY25 results: profit −68.2% YoY -1.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹81 cr | ₹1 cr | +348.3% | 5.8% | 0.24 |
| Mar 2026 | ₹71 cr | ₹1 cr | -92.9% | 0.2% | 0.11 |
| Dec 2025 | ₹73 cr | ₹0 cr | -94.4% | 4.3% | 0.06 |
| Sept 2025 | ₹56 cr | ₹0 cr | -95.4% | 2.1% | 0.04 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 65.99% | 65.99% | 65.99% | 65.99% |
| Foreign institutions (FII) | 0.00% | 0.00% | 0.00% | 1.74% |
| Domestic institutions (DII) | 2.56% | 2.56% | 2.56% | 0.02% |
| Mutual funds | — | — | — | — |
| Retail investors | 18.48% | 18.77% | 19.24% | 16.89% |
| Number of shareholders | 14,474 | 14,682 | 15,176 | 15,085 |
Common questions
What was Balaxi Pharmaceuticals Limited's latest quarterly profit?
Balaxi Pharmaceuticals Limited reported a net profit of ₹1 cr for the quarter ended Jun 2026 (+348.3% on the same quarter a year earlier), on revenue of ₹81 cr.
How much do promoters hold in Balaxi Pharmaceuticals Limited?
Promoters held 65.99% of Balaxi Pharmaceuticals Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Balaxi Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.23.
What is the 52-week high and low of Balaxi Pharmaceuticals Limited?
The 52-week high is ₹43.85 and the 52-week low is ₹15.2.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Balaxi Pharmaceuticals Limited | ₹19.15 | ₹106 cr | — | — | 0.6% | — | 0.23 | -55.3% |
| QMS Medical Allied Services Limited | ₹181.17 | ₹350 cr | 31.6 | — | 10.5% | 18.9% | 0.71 | +66.3% |
| Vijaypd Ceutical Limited | ₹76.05 | ₹149 cr | 29.6 | 2.8 | 11.8% | 9.2% | 0.7 | +70.9% |
| Aakaar Medical Technologies Limited | ₹71 | ₹101 cr | 15.2 | 1.8 | 17.1% | 25.8% | 0.34 | -15.5% |
| Vivo Bio Tech Ltd. | ₹13.72 | ₹31 cr | — | — | -2% | 8.3% | 0.72 | -31.9% |
| Mono Pharmacare Limited | ₹9.2 | ₹16 cr | 46.1 | 0.5 | 2.3% | 7.6% | 1.77 | -53.2% |
Compare BALAXI with QMSMEDI in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BALAXI in NSE Scanner →